NASDAQ:NERVMinerva Neurosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Minerva Neurosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $13.47 -0.74 (-5.21 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$12.41Now: $13.47▼$14.3050-Day Range$5.50MA: $9.56▼$14.7052-Week Range$4.01Now: $13.47▼$15.22Volume1.69 million shsAverage Volume451,129 shsMarket Capitalization$528.28 millionP/E RatioN/ADividend YieldN/ABeta1.79 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company' preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMinerva Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.80, Minerva Neurosciences has a potential upside of 54.4% from its current price of $13.47.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesMinerva Neurosciences has received 324 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMinerva Neurosciences has received 262 “underperform” votes. (Add your “underperform” vote.)Community SentimentMinerva Neurosciences has received 55.29% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote “Outperform” if you believe NERV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 12.00% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by Institutions80.39% of the stock of Minerva Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Minerva Neurosciences are expected to decrease in the coming year, from ($1.01) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -7.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -7.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMinerva Neurosciences has a P/B Ratio of 28.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NERV Previous Symbol CUSIPN/A CIK1598646 Webwww.minervaneurosciences.com Phone617-600-7373Debt Debt-to-Equity RatioN/A Current Ratio5.40 Quick Ratio5.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book28.66Profitability EPS (Most Recent Fiscal Year)($1.85) Net Income$-72,180,000.00 Net MarginsN/A Return on Equity-161.96% Return on Assets-72.61%Miscellaneous Employees13 Outstanding Shares39,219,000Market Cap$528.28 million Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:NERV Rates by TradingView Receive NERV News and Ratings via Email Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions How has Minerva Neurosciences' stock been impacted by COVID-19 (Coronavirus)? Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NERV shares have increased by 111.8% and is now trading at $13.47. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Minerva Neurosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Minerva Neurosciences. When is Minerva Neurosciences' next earnings date? Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Minerva Neurosciences. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences Inc (NASDAQ:NERV) issued its quarterly earnings data on Monday, May, 4th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.05. View Minerva Neurosciences' earnings history. What price target have analysts set for NERV? 5 equities research analysts have issued 1 year price targets for Minerva Neurosciences' shares. Their forecasts range from $17.00 to $26.00. On average, they expect Minerva Neurosciences' share price to reach $20.80 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price. View analysts' price targets for Minerva Neurosciences. What are Wall Street analysts saying about Minerva Neurosciences stock? Here are some recent quotes from research analysts about Minerva Neurosciences stock: 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (5/7/2020) 2. HC Wainwright analysts commented, "Valuation Our $22 price target for Minerva is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (5/31/2019) Has Minerva Neurosciences been receiving favorable news coverage? News articles about NERV stock have trended somewhat positive this week, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Minerva Neurosciences earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutMinerva Neurosciences. Are investors shorting Minerva Neurosciences? Minerva Neurosciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,820,000 shares, a decrease of 5.4% from the April 30th total of 2,980,000 shares. Based on an average daily volume of 392,500 shares, the short-interest ratio is presently 7.2 days. Approximately 9.0% of the shares of the stock are short sold. View Minerva Neurosciences' Current Options Chain. Who are some of Minerva Neurosciences' key competitors? Some companies that are related to Minerva Neurosciences include Prestige Consumer Healthcare (PBH), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), Epizyme (EPZM), Pacira Biosciences (PCRX), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Eidos Therapeutics (EIDX), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Arvinas (ARVN), Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND), Theravance Biopharma (TBPH) and Ironwood Pharmaceuticals (IRWD). View all competitors. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include PTC Therapeutics (PTCT), Inovio Pharmaceuticals (INO), Immunomedics (IMMU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), ImmunoGen (IMGN), VBI Vaccines (VBIV), Exelixis (EXEL), TG Therapeutics (TGTX) and Cara Therapeutics (CARA). Who are Minerva Neurosciences' key executives? Minerva Neurosciences' management team includes the following people: Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)Dr. Michael Davidson, Chief Medical Officer (Age 69)Mr. Richard Russell, Pres (Age 55)Mr. Joseph Reilly, Sr. VP & COO (Age 44) What is Minerva Neurosciences' stock symbol? Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV." Who are Minerva Neurosciences' major shareholders? Minerva Neurosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.33%), State Street Corp (1.31%), Geode Capital Management LLC (1.25%), Nuveen Asset Management LLC (1.03%), Acadian Asset Management LLC (0.48%) and Sphera Funds Management LTD. (0.43%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View institutional ownership trends for Minerva Neurosciences. Which major investors are selling Minerva Neurosciences stock? NERV stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., JPMorgan Chase & Co., Squarepoint Ops LLC, State Street Corp, GSA Capital Partners LLP, Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, and Venture Associates L Index III. View insider buying and selling activity for Minerva Neurosciences. Which major investors are buying Minerva Neurosciences stock? NERV stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Deutsche Bank AG, Russell Investments Group Ltd., Acadian Asset Management LLC, AQR Capital Management LLC, Geode Capital Management LLC, Two Sigma Advisers LP, and Trexquant Investment LP. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, and William F Doyle. View insider buying and selling activity for Minerva Neurosciences. How do I buy shares of Minerva Neurosciences? Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Minerva Neurosciences' stock price today? One share of NERV stock can currently be purchased for approximately $13.47. How big of a company is Minerva Neurosciences? Minerva Neurosciences has a market capitalization of $528.28 million. The biopharmaceutical company earns $-72,180,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe. What is Minerva Neurosciences' official website? The official website for Minerva Neurosciences is www.minervaneurosciences.com. How can I contact Minerva Neurosciences? Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
